ADAR1 Capital Management LLC Purchases Shares of 28,221 Pulmonx Co. (NASDAQ:LUNG)

ADAR1 Capital Management LLC acquired a new position in Pulmonx Co. (NASDAQ:LUNG) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 28,221 shares of the company’s stock, valued at approximately $192,000.

A number of other large investors have also recently made changes to their positions in the stock. Barclays PLC increased its holdings in Pulmonx by 1.8% in the 3rd quarter. Barclays PLC now owns 94,109 shares of the company’s stock worth $780,000 after acquiring an additional 1,679 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Pulmonx by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company’s stock worth $2,142,000 after purchasing an additional 2,363 shares during the period. Rhumbline Advisers increased its stake in shares of Pulmonx by 4.9% in the fourth quarter. Rhumbline Advisers now owns 53,503 shares of the company’s stock worth $363,000 after purchasing an additional 2,488 shares in the last quarter. American Century Companies Inc. raised its position in shares of Pulmonx by 8.8% during the 4th quarter. American Century Companies Inc. now owns 34,738 shares of the company’s stock valued at $236,000 after purchasing an additional 2,810 shares during the period. Finally, SG Americas Securities LLC lifted its stake in shares of Pulmonx by 27.0% during the 4th quarter. SG Americas Securities LLC now owns 15,555 shares of the company’s stock valued at $106,000 after buying an additional 3,310 shares in the last quarter. 91.04% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pulmonx

In other news, CFO Mehul Joshi sold 14,384 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.12, for a total transaction of $102,414.08. Following the transaction, the chief financial officer now owns 113,986 shares of the company’s stock, valued at approximately $811,580.32. The trade was a 11.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Geoffrey Beran Rose sold 5,779 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.13, for a total value of $41,204.27. Following the completion of the sale, the insider now owns 285,278 shares of the company’s stock, valued at approximately $2,034,032.14. This represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 147,986 shares of company stock worth $1,143,673 over the last 90 days. 5.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

LUNG has been the subject of a number of analyst reports. Citigroup began coverage on Pulmonx in a research note on Monday, March 10th. They issued a “buy” rating for the company. Jefferies Financial Group began coverage on Pulmonx in a research report on Monday, March 10th. They set a “buy” rating for the company. D. Boral Capital began coverage on Pulmonx in a research note on Monday, March 10th. They set a “buy” rating and a $17.00 target price on the stock. Morgan Stanley started coverage on Pulmonx in a research note on Monday, March 10th. They issued an “equal weight” rating for the company. Finally, Wells Fargo & Company reduced their price objective on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.75.

Pulmonx Price Performance

Shares of Pulmonx stock opened at $6.60 on Tuesday. The firm has a market cap of $262.65 million, a PE ratio of -4.58 and a beta of 0.61. The stock has a 50 day moving average of $7.24 and a 200 day moving average of $6.88. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. Pulmonx Co. has a 12 month low of $5.46 and a 12 month high of $10.01.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The firm had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. On average, research analysts expect that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.